Dominik Ellenrieder, Chairman, has been a medtech entrepreneur since 2001 active in different medtech segments. In 2000, he co-founded Kuros Therapeutics AG that was sold in 2002. In 2001, he joined Medartis AG as a shareholder and vice-chairman. In 2003 he joined the board of Sentec AG and bought the major shareholders out in 2006. In 2009, he co-founded QGel SA. He also acts as chairman of Sentec AG and QGel SA and as vice-chairman of Medartis Holding AG and Kuros Biosciences AG. Furthermore he is also active as a venture partner of Endeavour Vision in Geneva since 2007.
Reinhard J. Ambros, PhD, is Executive Director of Novartis Venture Fund. Previously, he worked with Novartis Corporate Finance where he held the position of Head of Group Strategic Planning for several years. He was responsible for post merger integrations at Novartis Corporate M & A and was global head BD & L cardiovascular and metabolic diseases at Novartis Pharma. Earlier in his career he had global leadership positions for key drug development projects at Novartis and Roche.
Martin Gertsch is an experienced Board Member and Financial Advisor in the life sciences industry. He serves as a Chairman of the Board of Santhera Pharmaceuticals and as Board Member of Evolva Holidng and the University Center of Dentistry, Basel (UZB). Up 2014, he served as Chief Financial Officer (CFO) of Acino Holding and Synthes EMEA and worked as CFO/COO at Delenex Therapeutics and ESBATech before. Prior to this he was CFO of the Straumann Group. He started his career at PricewaterhouseCoopers and also completed several executive-level programs at the lnternational Institute for Management Development (IMD).
Jeffrey Jump currently serves as Chairman of Manli Cardiology Ltd and Med Alliance SA, is an independent board director of Veryan Endovascular Ltd, Meryan Medical Ltd, and Impulse Dynamics. He previously served as chief executive officer of Biosensors, and Chairman of Biosensors Europe. He has held senior positions with Xitact SA, Embol-x Inc, Cardio Thoracic Systems Inc and Haemonetics Inc.
Erich Schlick, MD, joined Wellington Partners in October 2005. Before this, he served as Director and Head of 3i Healthcare Germany and as Deputy Sector Head 3i Healthcare Worldwide and was responsible for numerous successful investments. Prior to venture capital, Erich spent 15 years with BASF Pharma Knoll AG, 10 years thereof as an executive board member with worldwide responsibility for preclinical and clinical R&D.
Matthias Staehelin is a partner in the law firm Vischer with offices in Basel and Zurich. He is the lead partner of the firm’s life sciences group and co-heads Vischer's corporate practice. Prior to joining Vischer (or its predecessor) he worked in 1993/1994 with Cravath, Swaine & Moore in New York as foreign associate. He studied law at the University of Basel where he obtained also his PhD, in Freiburg i.B./Germany (graduate college), at the College of Europe, in Bruges/Belgium, where he obtained a Master of Advanced European Studies (MAES) and a Diplôme des Hautes Etudes Européennes (DHEE) as well as in Halifax/Canada. He is admitted to the bar in Switzerland and is qualified as public notary in the Cantons of Basel-Stadt and Basel-Landschaft. Matthias Staehelin is president of BioValley Basel and Treasurer of the BioValley Business Angels Club (BioBAC). He serves on the Board of Directors of privately held companies including Work in Progress as well as on the Board of Swiss subsidiaries of publicly traded companies. He is also member of the Supervisory Board of Fondation Internationale de Recherche Servier.
Damien Tappy is co-founder, President and Managing Partner of Endeavour Vision. Before co-founding Endeavour Vision in 2000, he was the founder and Director of the Start-up and Spin-off Program from the Swiss Federal Institute of Technology in Lausanne (EPFL). In parallel, he served as expert for new ventures creation at the Swiss Federal Commission for Technology and Innovation (CTI) in Bern.